In Melanoma, more than 40% of patients are unresponsive to existing first-line nivolumab (PD-1 mAb) plus ipilimumab (cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) mAb) therapies5, with a growing unmet need for novel regimens to overcome the targeted immunotherapy resistance6. Here, PDCD1 is linked to melanoma.